| 2025-01-30 12-15-27 | Back Pain in the Lumbar Spine is reduced by an average of 71% at 12 months after injection of 10±5 million Normoxic-Cultured Autologous Mesenchymal Stem Cells (MSCs) into a non-torn Intervertebral Disc (IVD) at L5-S1, L4-L5, or both levels |
| 2025-01-30 12-13-47 | Back Pain in the Lumbar Spine is reduced by an average of 69% at 6 months after injection of 10±5 million Normoxic-Cultured Autologous Mesenchymal Stem Cells (MSCs) into a non-torn Intervertebral Disc (IVD) at L5-S1, L4-L5, or both levels |
| 2025-01-30 12-11-56 | Back Pain in the Lumbar Spine is reduced by an average of 62% at 3 months after injection of 10±5 million Normoxic-Cultured Autologous Mesenchymal Stem Cells (MSCs) into a non-torn Intervertebral Disc (IVD) at L5-S1, L4-L5, or both levels |
| 2025-01-29 10-20-44 | 34% of people between 20-39 have an asymptomatic degenerated Intervertebral Disc (IVD) of the Lumbar Spine |
| 2025-01-29 10-17-29 | 56% of people between 20-39 have an asymptomatic bulging Intervertebral Disc (IVD) of the Lumbar Spine |
| 2025-01-29 10-19-30 | 21% of people between 20-39 have an asymptomatic herniated Intervertebral Disc (IVD) in the Lumbar Spine |